COVID-19 has caught even the most well-prepared companies off-guard, forcing many to rethink their performance expectations into 2021 and beyond. To help model the impact of a post-COVID-19 future, we've identified four key risks using historical information about total prescriptions and patient-level data.


Here's a look at our hypotheses based on our research, and what these risks might mean for pharma companies as the recovery begins.